Center for Behavioral Research and Services
Long Beach, California, 90813, United States
NCT Number: NCT01317784
The relevance of this research to public health is to make it possible to test for hepatitis C and syphilis at point of care so that people will receive their results immediately instead of requiring people to wait for at least a week to get their test results. This research will make rapid tests for HIV available that can detect HIV infection earlier and are more accurate than current tests available in the United States.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Long Beach, California, 90813, United States
This application addresses "Studies to improve access and utilization of HIV counseling and testing" for "HIV/AIDS and AIDS-related co-infections" such as "hepatitis C virus (HCV), other sexually transmitted infections (STIs)" that are part of PA-07-307 Drug Abuse Aspects of HIV/AIDS. The only rapid tests that are approved for use in the US currently are for HIV infection. Tests for other conditions such as hepatitis C (HCV) and syphilis are in use in other countries. In response to an Opportunity that the CDC published in the Federal Register, there are now candidate rapid test kits for HCV and syphilis available for experimental use in the US. Different combinations of rapid and standard tests will be offered to participants in a four-arm trial to assess which tests are accepted by the participants. Only a minority of clients at CBRS who have been offered the rapid test for HIV have accepted it. Those who chose rapid HIV tests were more likely to be male, educated, gay, young and White. They were less likely to be Black, or injection drug users. The proposed study has the potential to have a significant impact upon screening for HIV, syphilis, and HCV. Rapid tests have the potential to increase the receipt of test results, particularly among groups that are less likely to return for their results using traditional testing. The candidate tests are designed for Point of Care (either oral fluid and/or whole blood), and thus will require real-time testing, so the trial will be able to evaluate both the accuracy of the tests in settings of intended use and their acceptability to potential clients in real-world situations.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Choice of 16 different rapid tests. Only 12 manufacturer and names are shown because some are used with both blood and oral fluid. When they are used on both specimens, they are counted as two tests.
Other names: INSTITM HIV-1 Antibody Test (bioLytical Laboratories, Inc.), Determine HIV-1/2 Ag/Ab Combo (Alere, Inc.), DPP® HIV 1/2 Screen Assay (Chembio, Inc.), OraQuick HCV antibody test (Orasure), DPP® HCV Screen Assay (Chembio, Inc.), DPP® HIV-HCV Screen Assay (Chembio, Inc.), Multiplo Rapid HIV/HCV Antibody Test (MedMira, Inc.), DPP® Syphilis Screen & Confirm Assay (Chembio, Inc.), DPP® HIV-Syphilis Screen Assay (Chembio, Inc.), DPP® HIV-HCV-Syphilis Screen Assay (Chembio, Inc.), Multiplo Rapid HIV/HCV/HBV Antibody Test (MedMira, Inc.)
Choice of 10 different tests for HIV and hepatitis C.
Other names: INSTITM HIV-1 Antibody Test (bioLytical Laboratories, Inc.), Determine HIV-1/2 Ag/Ab Combo (Alere, Inc.), DPP® HIV 1/2 Screen Assay (Chembio, Inc.), OraQuick HCV antibody test (Orasure), DPP® HCV Screen Assay (Chembio, Inc.), DPP® HIV-HCV Screen Assay (Chembio, Inc.), Multiplo Rapid HIV/HCV Antibody Test (MedMira, Inc.)
Choice of 7 different tests for HIV and syphilis
Other names: INSTITM HIV-1 Antibody Test (bioLytical Laboratories, Inc.), Determine HIV-1/2 Ag/Ab Combo (Alere, Inc.), DPP® HIV 1/2 Screen Assay (Chembio, Inc.), DPP® Syphilis Screen & Confirm Assay (Chembio, Inc.), DPP® HIV-Syphilis Screen Assay (Chembio, Inc.)
Choice of 4 different tests for HIV only.
Other names: INSTITM HIV-1 Antibody Test (bioLytical Laboratories, Inc.), Determine HIV-1/2 Ag/Ab Combo (Alere, Inc.), DPP® HIV 1/2 Screen Assay (Chembio, Inc.)
Time frame: one day (day one of study)
Which tests do participants choose to receive when bundled in different combinations?
Time frame: one week
Is there a different return for test results rate for the different arms of the study?
California State University, Long Beach
Other
Acronym: BSARTA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05868005
Acquired Immunodeficiency Syndrome, Actinomycetales Infections
Almería, Andalusia, Spain
View Trial DetailsNCT01315054
Bacterial Infections, Bacterial Infections and Mycoses
Beijing, China
View Trial DetailsNCT01681420
Blood-Borne Infections, Chagas Disease
São Paulo, Brazil
View Trial DetailsNCT00926146
Blood-Borne Infections, Communicable Diseases
Los Angeles, California, United States
View Trial Details